Preventing pneumothorax during lung cancer treatment
Pleural Blood Patch for Lung Ablation: a Randomised Trial (Oxford Pleural Embolisation Trial - OxPET)
This study is testing if using a special technique called pleural blood patch can help prevent lung collapses in patients getting treatment for lung cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 106 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oxford University Hospitals NHS Trust Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Oxford) |
| Trial ID | NCT06651658 on ClinicalTrials.gov |
What this trial studies
This trial investigates the use of pleural embolization, specifically a technique known as pleural blood patch (PBP), to prevent pneumothorax in patients undergoing thermal ablation for lung cancer. Pneumothorax is a common complication that can lead to the need for chest drains, which are associated with additional morbidity. The study aims to assess the effectiveness of PBP in reducing the incidence of pneumothorax and the subsequent need for drainage procedures. By utilizing autologous blood to seal air leaks, the trial seeks to improve patient outcomes and recovery times following lung ablation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are clinically indicated for lung ablation.
Not a fit: Patients who are unable to proceed with the lung ablation procedure or have three or more lung lesions to be ablated in the same setting may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce complications and improve recovery for patients undergoing lung cancer treatment.
How similar studies have performed: Previous studies have shown success with similar techniques in reducing pneumothorax rates during lung biopsies, indicating potential for this approach in lung ablation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically indicated for lung ablation. * Willing and capable of giving informed consent. * Aged 18 years or above. Exclusion Criteria: * Unable to proceed to lung ablation procedure. * 3 or more lung lesions to be ablated in the same setting.
Where this trial is running
Oxford
- Oxford University Hospitals NHS Foundation Trust — Oxford, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Dr Yan-Lin Li Consultant Interventional Radiologist, EBIR FRCR FHKAM — Oxford University Hospitals NHS Foundation Trust/ University of Oxford
- Study coordinator: Dr Yan-Lin Li Consultant Interventional Radiologist, EBIR FRCR FHKAM
- Email: yan-lin.li@ouh.nhs.uk
- Phone: 44 1865 235746
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.